EMA to revise five-year road map in light of feedback
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is to revise its road map, which sets out its strategic development plans for the next five years to 2015, to take into account the feedback it has received so far. Part of the roadmap's vision is for regulators and industry to start working together earlier in the drug development process in order to improve the chances of approval (for the roadmap's proposals, see scripintelligence.com, 27 January 2010).